VYNE Therapeutics (VYNE) Total Non-Current Liabilities (2016 - 2024)
VYNE Therapeutics (VYNE) posted Total Non-Current Liabilities of $25000.0 for Q2 2024, down 98.18% on a QoQ basis from $1.4 million in Q1 2024, and down 99.61% year-over-year from $6.4 million in Q3 2023.
VYNE Therapeutics (VYNE) Total Non-Current Liabilities (2016 - 2024) Analysis & Trends
VYNE Therapeutics' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $25000.0 for Q2 2024.
- Quarterly Total Non-Current Liabilities fell 99.61% year-over-year to $25000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $25000.0 (down 99.61% YoY) and the FY2023 annual result came in at $1.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $25000.0 for Q2 2024 at VYNE Therapeutics, down from $1.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $58.6 million in Q2 2021 and bottomed at $25000.0 in Q2 2024.
- A 4-year average of $23.0 million and a median of $22.0 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 67.15% — and 2024, when it slumped 99.61%.
- VYNE Therapeutics' Total Non-Current Liabilities stood at $34.5 million in 2020, then plunged by 36.27% to $22.0 million in 2021, then plunged by 93.58% to $1.4 million in 2023, then tumbled by 98.23% to $25000.0 in 2024.
- Business Quant data shows VYNE's Total Non-Current Liabilities at $25000.0 in Q2 2024, $1.4 million in Q1 2024, and $1.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 25,000.00 |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 6.46 Mn |
| Jun 30, 2023 | 6.39 Mn |
| Mar 31, 2023 | 7.53 Mn |
| Sep 30, 2021 | 21.98 Mn |
| Jun 30, 2021 | 58.64 Mn |
| Mar 31, 2021 | 55.81 Mn |
| Dec 31, 2020 | 34.48 Mn |
| Sep 30, 2020 | 34.98 Mn |
| Jun 30, 2020 | 35.08 Mn |
| Mar 31, 2020 | 34.41 Mn |
| Dec 31, 2019 | 34.26 Mn |
| Dec 31, 2018 | 9.54 Mn |
| Sep 30, 2018 | 8.06 Mn |
| Jun 30, 2018 | 8.65 Mn |
| Mar 31, 2018 | 14.76 Mn |
| Dec 31, 2017 | 14.55 Mn |
| Dec 31, 2016 | 12.43 Mn |